Payment overview · 2025
General Payments
$183.01
6 reported records · 5 companies
Healthcare provider profile · identity verified
Khurram Butt, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · DENNISON, OH · NPI 1437149176
Verified facts
What the public records show
CMS Open Payments records show Khurram Butt, M.D. received $183.01 in general payments during 2025 across 6 reported records.
Medtronic, Inc. accounted for 40.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$74.21 | 40.5% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $45.90 | 25.1% | 2 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.81 | 13.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.00 | 11.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.09 | 9.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $183.01 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AVEIR Normalized: aveir |
Device | Abbott Laboratories | $45.90 | 2 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $24.81 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 444 | 68 |
| Omeprazole | Omeprazole | 422 | 68 |
| Simvastatin | Simvastatin | 357 | 47 |
| Alprazolam | Alprazolam | 354 | 47 |
| Lisinopril | Lisinopril | 325 | 62 |
| Atorvastatin Calcium | Atorvastatin Calcium | 313 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 259 | 55 |
| Trazodone Hcl | Trazodone Hcl | 242 | 43 |
| Metformin Hcl | Metformin Hcl | 222 | 34 |
| Gabapentin | Gabapentin | 198 | 38 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 40 |
| Glipizide Er | Glipizide | 158 | 31 |
| Clonazepam | Clonazepam | 154 | 20 |
| Alendronate Sodium | Alendronate Sodium | 153 | 27 |
| Furosemide | Furosemide | 152 | 41 |
| Lorazepam | Lorazepam | 151 | 21 |
| Losartan Potassium | Losartan Potassium | 144 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 135 | 35 |
| Topiramate | Topiramate | 127 | 21 |
| Buspirone Hcl | Buspirone Hcl | 126 | 23 |
| Fenofibrate | Fenofibrate Nanocrystallized | 124 | 21 |
| Tramadol Hcl | Tramadol Hcl | 121 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 108 | 15 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 108 | 24 |
| Sertraline Hcl | Sertraline Hcl | 108 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 106 | 28 |
| Mirtazapine | Mirtazapine | 100 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 90 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 90 | 19 |
| Januvia | Sitagliptin Phosphate | 84 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 83 | 20 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 18 |
| Montelukast Sodium | Montelukast Sodium | 80 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 80 | 20 |
| Azelastine Hcl | Azelastine Hcl | 79 | 38 |
| Potassium Chloride | Potassium Chloride | 77 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 76 | 23 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 69 | 16 |
| Prednisone | Prednisone | 69 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | 15 |
| Azithromycin | Azithromycin | 64 | 49 |
| Bupropion Xl | Bupropion Hcl | 62 | suppressed |
| Synthroid | Levothyroxine Sodium | 60 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 59 | 17 |
| Glipizide | Glipizide | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 57 | 11 |
| Ezetimibe | Ezetimibe | 55 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 53 | suppressed |
| Eliquis | Apixaban | 51 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 50 | 33 |
| Allopurinol | Allopurinol | 46 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 14 |
| Meloxicam | Meloxicam | 45 | suppressed |
| Carvedilol | Carvedilol | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 11 |
| Diazepam | Diazepam | 43 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 33 |
| Famotidine | Famotidine | 41 | suppressed |
| Ibuprofen | Ibuprofen | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | suppressed |
| Fenofibrate | Fenofibrate | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 36 | 13 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 34 | 14 |
| Baclofen | Baclofen | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 32 | suppressed |
| Ozempic | Semaglutide | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Xarelto | Rivaroxaban | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 27 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 11 |
| Ketoconazole | Ketoconazole | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Pregabalin | Pregabalin | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 11 |
| Methimazole | Methimazole | 17 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Spironolactone | Spironolactone | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 11 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Folic Acid | Folic Acid | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Niacin Er | Niacin | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Donepezil Hcl | Donepezil Hcl | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $183.01 · 6 records | Medtronic, Inc. | AVEIR, Dexcom G6 Transmitter, GVOKE HYPOPEN | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error